Despite encouraging clinical evidence, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering substantial opposition from managed care entities. The insurers are typically building limitations to access, including steep price restrictions and PA that limit consumer opportunity. Market indicate t